<DOC>
	<DOCNO>NCT00128167</DOCNO>
	<brief_summary>The primary objective study estimate relative efficacy assess safety CAIV-T compare TIV .</brief_summary>
	<brief_title>Trivalent , Live , Cold Adapted Influenza Vaccine ( CAIV-T ) Against Inactivated Influenza Vaccine ( TIV ) Children 6â€“59 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Age 659 month age ( yet reach 5th birthday ) Parent guardian available telephone Available illness visit clinic home influenza surveillance period Written inform consent ( Health Insurance Portability Accountability Act [ HIPAA ] authorization U.S . Participants ) obtain participant 's parent legal guardian Ability parent/guardian understand comply requirement protocol History hypersensitivity component CAIVT inactivate influenza vaccine , include egg egg protein History hypersensitivity gentamicin Any known immunosuppressive condition immune deficiency disease ( include HIV infection ) , ongoing receipt immunosuppressive therapy History GuillainBarre syndrome Medicallydiagnosed wheezing , bronchodilator use , steroid use ( systemic inhale ) within previous 42 day parent report chart review ( e.g. , child recent persistent asthma exclude ) , history severe asthma Acute febrile ( &gt; 100.0 degree F &gt; 37.8 degree C oral equivalent ) illness acute respiratory illness , include sore throat , within three day prior enrollment Receipt investigational product within 30 day prior enrollment expect receipt study Use aspirin salicylatecontaining product 30 day prior enrollment expect receipt study Use antiinfluenza medication ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 14 day prior enrollment expect receipt study Receipt blood product within 90 day prior vaccination expect receipt study Administration live virus vaccine within 30 day prior enrollment , receipt another live virus vaccine expect within 30 day study vaccination Administration inactivate vaccine within 14 day prior enrollment receipt another inactivate vaccine expect within 14 day prior enrollment receipt another inactivate vaccine expect within 14 day study vaccination Close contact severely immunocompromised ( e.g. , transplant recipient ) Family member household contact employee research center otherwise involved conduct study Any condition , opinion investigator , might interfere interpretation evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>